<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00488449</url>
  </required_header>
  <id_info>
    <org_study_id>HMA110015</org_study_id>
    <nct_id>NCT00488449</nct_id>
  </id_info>
  <brief_title>Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers</brief_title>
  <official_title>A Two-Part Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Oral Doses of GSK256073A, in a Randomized, Single-Blind, Dose Escalation Study in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects of single and repeat doses of GSK256073
      with placebo in HVT subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AEs, 12-Lead ECG, vital signs, nursing/physician observation, safety lab tests, flushing</measure>
    <time_frame>throughout the study (Parts A &amp;B)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC and Cmax</measure>
    <time_frame>throughout the study (Part A &amp; B)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Measures of accumulation ratios</measure>
    <time_frame>throughout the study (Ro, Rp, and Rs)[Part B]</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax, t½, Ae, and CLr (Parts A &amp; B) Cmax, ss, Ct, t½, Ae, CLr, and accumulation ratios (Part B)</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD response: NEFA and TG (6 and 24 hours post- dose)</measure>
    <time_frame>(6 and 24 hours post- dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL, HDL, ApoA1, ApoA2, Apo B and Lp(a)</measure>
    <time_frame>on Days 1, 14, and 15.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of GSK256073 to derive pharmacokinetic parameters following repeat dose administration.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid levels</measure>
    <time_frame>on Days 1, 14, and 15</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy Subjects</condition>
  <condition>Dyslipidaemias</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK256073A tablets</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Healthy Adult males or females between 18 and 55 years of age, inclusive.

          -  Female subjects must be of non-childbearing potential

          -  Body weight &gt; 50 kg (110 pounds) and body mass index (BMI) 19 and 31 where:

          -  Subjects with QTc &lt; 450 msec at screening (or QTc &lt; 480 msec for subjects with Bundle
             Branch Block).

          -  A signed and dated written informed consent prior to admission to the study.

          -  The subject is able to understand and comply with protocol requirements, instructions
             and protocol-stated restriction

        Exclusion criteria:

          -  Systolic blood pressure &lt; 100 mmHg or 150 mmHg and/or diastolic blood pressure = 100
             mmHg at screening.

          -  History of significant cardiac arrhythmias

          -  Active peptic ulcer disease (PUD) and/or history of PUD within 1 year.

          -  A serum uric acid concentration 8mg/dL

          -  Screening test positive for H. Pylori using the non-radioactive breath test

          -  History of gout and/or hyperuricemia

          -  History of Gilbert's syndrome

          -  A serum creatinine concentration above the normal reference range

          -  History of kidney stones

          -  PT and/or aPTT above the reference range

          -  History of recurrent indigestion, stomach upset or diarrhea

          -  Liver function tests (LFTs) or creatinine phosphokinase (CPK) 1.5X ULN

          -  Screening stool test positive for occult blood

          -  Screening peripheral blood smear with abnormal RBCs

          -  CBC, MCV, and/or reticulocyte count corrected for haemoglobin level above the
             reference range at screening

          -  Reduced G6PD activity

          -  Serum haptoglobin outside the reference range at screening

          -  Total serum LDH &gt; 1.25% above the ULN at screening

          -  Positive HIV, Hepatitis B or Hepatitis C at screening

          -  The subject has a positive pre-study urine drug/ serum alcohol screen.

          -  History of alcohol consumption exceeding, on average, 7 drinks/week for women or 14
             drinks/week for men within 6 months of the first dose of study medication or a
             positive alcohol test at screening

          -  History of use of tobacco or nicotine containing products within 6 months of screening
             or a positive urine cotinine screen

          -  Use of prescription (including hormone replacement therapy) or non-prescription drugs
             and vitamins within 7 days or 5 half-lives prior to administration of study
             medication. An exception is acetaminophen which is allowed at doses of 2g/day.

          -  Use of dietary/herbal supplements within 14 days prior to treatment with study
             medication

          -  Treatment with an investigational drug within 30 days or 5 half-lives (whichever is
             longer) prior to dosing.

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day.

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the physician responsible,
             contraindicates their participation.

          -  Where participation in study would result in donation of blood in excess of 500 mL
             within a 56 day period.

          -  Unwillingness of male subjects to use a condom/spermicide

          -  Pregnant or nursing women.

          -  History of flushing (&gt;1 episode annually).

          -  Fasting blood glucose 110 mg/dl and/or history of type I or type II DM

          -  History of intra-ocular pathology

          -  History of recurrent gum bleeding

          -  History of bleeding haemorrhoids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2007</study_first_submitted>
  <study_first_submitted_qc>June 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2007</study_first_posted>
  <last_update_submitted>May 31, 2012</last_update_submitted>
  <last_update_submitted_qc>May 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dose Escalation</keyword>
  <keyword>GSK256073A,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

